Crossmark

Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center

Crossref DOI link: https://doi.org/10.1186/s43046-020-00025-5

Published Online: 2020-03-04

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fayaz, Salah

Eissa, Heba El-Sayed

Demian, Gerges Attia http://orcid.org/0000-0002-4983-508X
License Information

Text and Data Mining valid from 2020-03-04

Version of Record valid from 2020-03-04
More Information

Article History

Received: 24 September 2019

Accepted: 13 February 2020

First Online: 4 March 2020

Ethics approval and consent to participate

: The research was approved by the scientific committee, Kuwait Cancer Control Center, both scientifically and ethically. Being a retrospective study, there was no consent for patients’ participation required in the study.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below